The aim of the present study was to investigate the efficacy and clinical tolerability of the specific
leukotriene B4 receptor antagonist
VML295 in the treatment of stable plaque
psoriasis. Immunohistochemical and flow cytometrical methods were used to assess the effects on
inflammation and epidermal proliferation.
VML295 in the treatment of chronic plaque
psoriasis was shown to be safe and well tolerated.
After treatment, there was a statistically significant difference between patients treated with
VML295 and patients treated with placebo with respect to the
leukotriene B4-induced CD11b up-regulation on the cell surface of polymorphonuclear leukocytes derived from peripheral blood. Ex vivo CD11b up-regulation in the VML295-treated group was completely inhibited after 7 days of treatment (P = 0.001). This effect persisted until the end of the treatment period (P = 0.004 on day 15 and P < 0.0001 after 4 weeks), whereas CD11b up-regulation in the placebo group remained unaffected. There was no statistically significant difference in the median
psoriasis area and severity index between the treatment groups at the end of the treatment period. During treatment, no significant histological changes were observed in the markers for cutaneous
inflammation and epidermal proliferation. Although not statistically significant, a tendency for the increased expression of some markers of cutaneous
inflammation and epidermal proliferation was observed after 1 week of treatment with
VML295, and a decreased expression of these markers was seen after 4 weeks of treatment with
VML295. This observation could indicate anti-inflammatory effects of
VML295 appearing between 2 and 4 weeks after the start of treatment.